Algorithm foundations with ML focus
Master core algorithms plus ML-specific problems like feature engineering, data processing pipelines, and optimization challenges.
0 roles from funded startups and hidden sources. Posted
minutes ago. Updated every 60 seconds
ML engineering interviews blend algorithms, system design, and domain expertise.. Explore key insights and preparation tips to help you excel in your interview process.
Master core algorithms plus ML-specific problems like feature engineering, data processing pipelines, and optimization challenges.
Design scalable ML pipelines, real-time inference systems, and data processing architectures that handle production ML workloads.
Training Pipelines
Distributed training & model versioning
Inference Systems
Real-time prediction & batch processing
Data Architecture
Feature stores & streaming pipelines
Different companies emphasize different aspects of ML engineering based on their core products and scale challenges.
Meta
Recommendation systems & large-scale feature engineering
Uber
Real-time ML & geospatial optimization algorithms
Compare cost-of-living buying power and how crowded the market is versus other major tech cities—so you can focus your search where the odds fit your goals.
Baltimore offers exceptional ROI for ML engineers with housing costs approximately 65% lower than San Francisco. Your $120K-140K salary stretches significantly further, enabling homeownership in desirable neighborhoods like Federal Hill or Canton while maintaining proximity to major biotech and defense contractors.
Baltimore's ML job market shows 28% saturation versus 78% in San Francisco. The Johns Hopkins corridor and growing defense tech sector create strong demand with manageable competition.

New roles go live every minute and the earliest applicants win. Get the freshest, verified listings delivered straight to your inbox before most job seekers ever see them.
👉 Get free daily job postsPearl Diagnostics is a Baltimore-based biotech spun out of Johns Hopkins University in 2014 that builds non-invasive urine-based diagnostic tests for lung infections. Its flagship MycoMEIA Aspergillus urine assay, which received FDA 510(k) clearance in August 2025 and CE approval for the EU, replaces invasive bronchoalveolar lavage procedures used to detect aspergillosis in transplant recipients, cancer patients, and immunocompromised individuals. The company is extending the same antigen-detection platform to other fungal and bacterial pathogens, including a Pseudomonas assay for cystic fibrosis patients.
Raised
$11.2M
Series A · 2026
Key contacts
-
Leadership & hiring contacts indexed
HQ market
Baltimore, Maryland
United States